Liquidia Corporation (LQDA) has reported approximately $300.3 million in sales for its lead drug, Yutrepia, during the first half of 2026, following its launch in June 2025. The drug, approved by the FDA in May 2025 for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has seen robust commercial uptake, with about 5,900 unique prescriptions written and over 5,000 patients initiated on therapy as of July 31, 2026.
Yutrepia captured nearly 30% of the inhaled market’s net revenues in Q2 2026, contributing to Liquidia’s fourth consecutive profitable quarter. The inhaled prostacyclin market grew from $573 million to $607 million in the first two quarters of 2026, a 6% increase sequentially. Liquidia anticipates generating more than $1 billion in net revenues from Yutrepia in 2027.
The inhaled therapy market is competitive, with Yutrepia facing rivals such as United Therapeutics’ Tyvaso and other treatments from Johnson & Johnson. Year-to-date, Liquidia’s share price has jumped 115.5%, significantly outperforming the industry average growth of 5.7%.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
